Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992;31(2):167-9.
doi: 10.1007/BF00685106.

Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck

S Urba  1 , J Doroshow, C Cripps, F Robert, E Velez-Garcia, B Dallaire, D Adams, R Carlson, A Grillo-Lopez, J Gyves
Affiliations
Free article
Clinical Trial

Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck

S Urba et al. Cancer Chemother Pharmacol. 1992.
Free article

Abstract

A total of 19 patients with advanced squamous-cell carcinoma of the head and neck who had not previously been exposed to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given intravenously at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 7 patients (37%) experiencing grade 3 or 4 toxicity. In all, 16 patients who were evaluable for efficacy showed no objective response. We conclude that brequinar given at this dose and on this schedule has no significant activity in advanced squamous-cell carcinoma of the head and neck.

PubMed Disclaimer

References

    1. Eur J Cancer Clin Oncol. 1989 Oct;25(10):1403-11 - PubMed
    1. Cancer Res. 1985 Nov;45(11 Pt 1):5563-8 - PubMed
    1. Cancer Res. 1990 Aug 1;50(15):4595-9 - PubMed
    1. Cancer Res. 1986 Oct;46(10):5014-9 - PubMed
    1. Cancer Res. 1989 Aug 15;49(16):4648-53 - PubMed